Week of August 13, 2012: Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More
Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More.
Bristol-Myers Squibb (BMS) has successfully completed its tender offer of Amylin Pharmaceuticals through its wholly owned subsidiary, B&R Acquisition Company, for all outstanding shares of common stock of Amylin at a purchase price of approximately $31 per share. Read More
Pfizer and AstraZeneca have entered into an agreement for the OTC rights for Nexium (esomeprazole magnesium), for treating gastroesophageal reflux disease. Under the agreement, Pfizer will acquire the exclusive global rights to market Nexium for the approved OTC indications in the US, Europe, and the rest of the world. Under the agreement, Pfizer will make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales. Read More
The CRO Quintiles has acquired Expression Analysis, a provider of genomics testing and analysis to biopharmaceutical, academic, government, and nonprofit clients. Read More
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
